Pharos iBio KRX:388870KOSDAQ
파로스아이바이오 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days5
DART filings, 7 days0
Articles tracked5since Sep 11
In Q2 2026, Pharos iBio reported an operating loss of ₩2.3bn. Pharos iBio (파로스아이바이오) appeared in 5 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Sep 29 with 5 articles. The most common catalyst was tech & capacity (2).
Filing signals 4 quarters of losses Screener
Pharos iBio quarterly results consolidated, KRW
| Quarter | Operating profit | Net income |
|---|---|---|
| Q2 2026 | −₩2.3bn | −₩2.3bn |
| Q1 2026 | −₩2.4bn | −₩2.2bn |
| Q4 2025 derived | −₩2.9bn | −₩3.1bn |
| Q3 2025 | −₩3.0bn | −₩1.8bn |
| Q2 2025 | −₩2.4bn | −₩2.8bn |
| Q1 2025 | −₩3.1bn | −₩3.0bn |
| Q4 2024 derived | −₩2.9bn | −₩2.2bn |
| Q3 2024 | −₩3.0bn | −₩2.5bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Pharos iBio top stories 2 weeks, by number of outlets
- 1
- 2
- 3
Latest Pharos iBio news Korean headlines
-
파로스아이바이오, 한·호주 생명과학 심포지엄 참여
2 more on this story · 2 outlets
- 파로스아이바이오, 한·호주 생명과학 심포지엄 초청 연사 참여뉴스핌 · Sep 29 14:59
- 파로스아이바이오, 한-호주 생명과학 심포지엄 참여⋯“글로벌 이노베이션 확대”브릿지경제 · Sep 29 15:22